Novartis’ Afinitor Phase III trial fails to meet primary end-point
Switzerland-based Novartis’ Phase III trial of advanced liver cancer drug, Afinitor (everolimus), did not meet the primary end-point of overall survival benefit in patients with advanced hepatocellular carcinoma (HCC) after progression on or intolera…
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news
More News: Cancer | Cancer & Oncology | Carcinoma | Hepatocellular Carcinoma | Liver | Liver Cancer | Pharmaceuticals | Urology & Nephrology